# US 6,730,301 B1 · MCP-1 receptor antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,301 B1
- Document ID: US6730301B1
- Status: Granted
- Kind: B1
- Application number: 09/625,573
- Filed: 2000-07-25
- Granted: 2004-05-04
- Earliest claimed: 1994-01-13
- Assignees: The Regents of the University of California
- Inventors: Israel R. Charo; Shaun R. Coughlin
- Web page: https://patentgrep.com/patent/US6730301B1

## CPC

- C07K 14/7158: {for chemokines}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates.

## Claims

### Claim 1

A method of making an antibody that binds MCP-1 receptor polypeptide comprising:
(a) immunizing an animal with the polypeptide comprising SEQ ID NO: 4;
(b) isolating antibody-producing cells from the animal;
(c) fusing the antibody-producing cells with immortalized cells in culture to form monoclonal antibody-producing hybridoma cells;
(d) culturing the hybridoma cells; and
(e) isolating from the culture monoclonal antibodies which bind to the MCP-1 receptor polypeptide.

### Claim 2 (depends on 1)

An antibody made by the method of claim 1.

### Claim 3

An antibody or binding fragment thereof which binds MCP-1 receptor polypeptide, wherein the polypeptide:
comprises the amino acid sequence of SEQ ID NO: 4.

### Claim 4 (depends on 3)

The antibody of claim 3, wherein the antibody is a humanized antibody.

### Claim 5 (depends on 3)

A composition comprising an antibody according to claim 3, and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 3)

The antibody of claim 3, wherein the antibody is labeled with a detectable label.

### Claim 7 (depends on 6)

The antibody of claim 6, wherein the detectable label is a radioactive isotope.

### Claim 8 (depends on 3)

The antibody of claim 3, wherein the antibody is a monoclonal antibody.

### Claim 9 (depends on 8)

A cell line producing the monoclonal antibody of claim 8.

### Claim 10 (depends on 9)

The cell line of claim 9 that is a eukaryotic cell line.

### Claim 11 (depends on 9)

The cell line of claim 9 that is a prokaryotic cell line.

### Claim 12 (depends on 3)

The antibody of claim 3, wherein the binding of the antibody or the fragment to the MCP-1 receptor polypeptide results in neutralization of activity of the binding MCP-1 polypeptide.
